Biognosys

The agreement brings together Biognosys' Spectronaut Pulsar DIA software and Waters' SONAR data-independent acquisition mass spectrometry method.

The company said it plans to use the funds to extend its commercial operations and develop new products broadly aimed at the life sciences research market.

As researchers continue to explore uses for DDA and DIA workflows, mass spec advances are enabling both methods to generate larger and more complete data sets.

The agreement involves Thermo Fisher's Orbitrap mass specs and Biognosys' Spectronaut Pulsar software for data-independent acquisition studies.

The company has licensed the Limited Proteolysis technology developed by ETH Zurich Professor Paola Picotti, which can assess proteome-wide structural changes.

Called CanPathPro, the research consortium aims to combine omics data and systems biology tools into a single commercial platform for testing cancer hypotheses.

The firm, which will open a Boston office at the end of Q1, did not disclose the amount raised but said it was in the "mid-single-digit millions" of dollars.

The effort will use Biognosys' HRM method to complement its MALDI-TOF approach to biomarker work, a company official said.

The collaboration is focused on using Biognosys' HRM mass spec technology to facilitate Biodesix's companion diagnostic work.

With sales growing at a double-digit clip, the Swiss proteomics firm is carving out a market for its mass spec-based protein quantitation services.

Pages

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.